Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second view: Evaluating the 52-Week Efficacy and Safety study of SKYRIZI (risankizumab) by AbbVie in Plaque Psoriasis Patients released at AAD 2023

Ticker(s): ABBV

Who's the expert?

Institution: Private Practice

Prescribed skyrizi to 75 patients with plaque psoriasis
Clinical and cosmetic dermatologist since 1986

Interview Goal

To discuss the standard of care for plaque psoriasis and the use of SKYRIZI (risankizumab) by AbbVie and evaluate the 52-Week Efficacy and Safety study of SKYRIZI (risankizumab) in Plaque Psoriasis Patients released at the American Academy of Dermatology Annual Meeting 2023

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.